Why the study?
Beyond pulmonary vein isolation, the ablation strategy for persistent AF remains controversial, with substrate ablation potentially causing impaired atrial physiology and complex re-entries.
Does the MARSHALL-PLAN ablation strategy improve procedural success and rhythm outcomes in patients with persistent atrial fibrillation?
Does the MARSHALL-PLAN ablation strategy improve procedural success and rhythm outcomes in patients with persistent atrial fibrillation?
The MARSHALL-PLAN ablation strategy is feasible and provides excellent short-term freedom from arrhythmia recurrence in patients with persistent atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports MARSHALL-PLAN feasibility in persistent AF; leaves open comparative efficacy versus standard ablation in randomized trials.
INTRODUCTION: Beyond pulmonary veins (PV) isolation, the ablation strategy for persistent atrial fibrillation (AF) remains controversial. Substrate ablation may provide a high termination rate but at the cost of impaired atrial physiology and recurrent complex re-entries. To overcome these pitfalls, we investigated a new lesion set based on important anatomical considerations. METHODS AND RESULTS: The case series included 10 consecutive patients with persistent AF. Three atrial structures were successively targeted: (1) coronary sinus and vein of Marshall (CS-VOM) musculature elimination; (2) PVs isolation; and (3) anatomical isthmuses block. The lesion set completion was the procedural endpoint. Step 1: VOM ethanol infusion was feasible in all cases (mean time of 33.4 ± 9.4 minutes), mean radiofrequency (RF) time for CS-VOM bundles was 14.4 ± 6.9 minutes. Step 2: mean RF time for PV isolation was 27.7 ± 9.3 minutes. Step 3: mean RF time for mitral, roof, and cavotricuspid lines was 5.7 ± 2.3, 8.1 ± 4.3, and 5.9 ± 1.9 minutes, respectively. The lesion set was achieved in all patients. Mean procedure time was 270 ± 29.9 minutes. AF termination and noninducibility were, respectively, obtained in 50% and 90% of the patients. After a 6-month follow-up, all patients were free from arrhythmia recurrence. CONCLUSION: The present case series reports a new ablation strategy systematically targeting anatomical structures previously identified as possibly involved in the fibrillatory process and the recurrent tachycardias. The resulting lesion set provides good short-term outcomes. Although promising, these preliminary results need to be confirmed in the larger prospective study.
No takes yet. Share an insight, caveat, or question.
Pambrun et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: